Real life experiences in HCV management in 2018

M. Viganò; M. Andreoni; C.F. Perno; A. Craxì; A. Aghemo; A. Alberti; P. Andreone; S. Babudieri; S. Bonora; M.R. Brunetto; R. Bruno; S. Bruno; V. Calvaruso; N. Caporaso; F. Cartabellotta; F. Ceccherini-Silberstein; V. Cento; A. Ciancio; P. Colombatto; N. Coppola; V. Di Marco; G. Di Perri; S. Fagiuoli; G.B. Gaeta; A. Gasbarrini; P. Lampertico; A. Pellicelli; T. Prestileo; M. Puoti; G. Raimondo; G. Rizzardini; G. Taliani; A.L. Zignego

doi:10.1080/14787210.2019.1563755

Real life experiences in HCV management in 2018

M. Viganò, M. Andreoni, C.F. Perno, A. Craxì, A. Aghemo, A. Alberti, P. Andreone, S. Babudieri, S. Bonora, M.R. Brunetto, R. Bruno, S. Bruno, V. Calvaruso, N. Caporaso, F. Cartabellotta, F. Ceccherini-Silberstein, V. Cento, A. Ciancio, P. Colombatto, N. CoppolaV. Di Marco, G. Di Perri, S. Fagiuoli, G.B. Gaeta, A. Gasbarrini, P. Lampertico, A. Pellicelli, T. Prestileo, M. Puoti, G. Raimondo, G. Rizzardini, G. Taliani, A.L. Zignego

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	117-128
Number of pages	12
Journal	Expert Review of Anti-Infective Therapy
Volume	17
Issue number	2
DOIs	https://doi.org/10.1080/14787210.2019.1563755
Publication status	Published - 2019

Keywords

Antiviral therapy
chronic liver disease
DAAs
HCV
hepatitis C virus
antivirus agent
glecaprevir plus pibrentasvir
nonstructural protein 5A inhibitor
pibrentasvir
sofosbuvir
sofosbuvir plus velpatasvir plus voxilaprevir
velpatasvir
antiviral resistance
antiviral susceptibility
antiviral therapy
decompensated liver cirrhosis
disease burden
drug efficacy
drug response
drug safety
health care access
hepatitis B
Hepatitis B virus
hepatitis C
Hepatitis C virus
human
Human immunodeficiency virus infection
Italy
kidney failure
liver cell carcinoma
liver fibrosis
mixed infection
nonhuman
practice guideline
Review
viral clearance

Access to Document

10.1080/14787210.2019.1563755

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060583062&doi=10.1080%2f14787210.2019.1563755&partnerID=40&md5=845cca1d70a38d295808a9fecc864e26

Cite this

Viganò, M., Andreoni, M., Perno, C. F., Craxì, A., Aghemo, A., Alberti, A., Andreone, P., Babudieri, S., Bonora, S., Brunetto, M. R., Bruno, R., Bruno, S., Calvaruso, V., Caporaso, N., Cartabellotta, F., Ceccherini-Silberstein, F., Cento, V., Ciancio, A., Colombatto, P., ... Zignego, A. L. (2019). Real life experiences in HCV management in 2018. Expert Review of Anti-Infective Therapy, 17(2), 117-128. https://doi.org/10.1080/14787210.2019.1563755

Real life experiences in HCV management in 2018. / Viganò, M.; Andreoni, M.; Perno, C.F.; Craxì, A.; Aghemo, A.; Alberti, A.; Andreone, P.; Babudieri, S.; Bonora, S.; Brunetto, M.R.; Bruno, R.; Bruno, S.; Calvaruso, V.; Caporaso, N.; Cartabellotta, F.; Ceccherini-Silberstein, F.; Cento, V.; Ciancio, A.; Colombatto, P.; Coppola, N.; Di Marco, V.; Di Perri, G.; Fagiuoli, S.; Gaeta, G.B.; Gasbarrini, A.; Lampertico, P.; Pellicelli, A.; Prestileo, T.; Puoti, M.; Raimondo, G.; Rizzardini, G.; Taliani, G.; Zignego, A.L.

In: Expert Review of Anti-Infective Therapy, Vol. 17, No. 2, 2019, p. 117-128.

Research output: Contribution to journal › Article › peer-review

Viganò, M, Andreoni, M, Perno, CF, Craxì, A, Aghemo, A, Alberti, A, Andreone, P, Babudieri, S, Bonora, S, Brunetto, MR, Bruno, R, Bruno, S, Calvaruso, V, Caporaso, N, Cartabellotta, F, Ceccherini-Silberstein, F, Cento, V, Ciancio, A, Colombatto, P, Coppola, N, Di Marco, V, Di Perri, G, Fagiuoli, S, Gaeta, GB, Gasbarrini, A , Lampertico, P, Pellicelli, A, Prestileo, T, Puoti, M, Raimondo, G, Rizzardini, G, Taliani, G & Zignego, AL 2019, 'Real life experiences in HCV management in 2018', Expert Review of Anti-Infective Therapy, vol. 17, no. 2, pp. 117-128. https://doi.org/10.1080/14787210.2019.1563755

Viganò, M. ; Andreoni, M. ; Perno, C.F. ; Craxì, A. ; Aghemo, A. ; Alberti, A. ; Andreone, P. ; Babudieri, S. ; Bonora, S. ; Brunetto, M.R. ; Bruno, R. ; Bruno, S. ; Calvaruso, V. ; Caporaso, N. ; Cartabellotta, F. ; Ceccherini-Silberstein, F. ; Cento, V. ; Ciancio, A. ; Colombatto, P. ; Coppola, N. ; Di Marco, V. ; Di Perri, G. ; Fagiuoli, S. ; Gaeta, G.B. ; Gasbarrini, A. ; Lampertico, P. ; Pellicelli, A. ; Prestileo, T. ; Puoti, M. ; Raimondo, G. ; Rizzardini, G. ; Taliani, G. ; Zignego, A.L. / Real life experiences in HCV management in 2018. In: Expert Review of Anti-Infective Therapy. 2019 ; Vol. 17, No. 2. pp. 117-128.

@article{68d4493b587346b1957db9f48d5e2ae0,

title = "Real life experiences in HCV management in 2018",

keywords = "Antiviral therapy, chronic liver disease, DAAs, HCV, hepatitis C virus, antivirus agent, glecaprevir plus pibrentasvir, nonstructural protein 5A inhibitor, pibrentasvir, sofosbuvir, sofosbuvir plus velpatasvir plus voxilaprevir, velpatasvir, antiviral resistance, antiviral susceptibility, antiviral therapy, decompensated liver cirrhosis, disease burden, drug efficacy, drug response, drug safety, health care access, hepatitis B, Hepatitis B virus, hepatitis C, Hepatitis C virus, human, Human immunodeficiency virus infection, Italy, kidney failure, liver cell carcinoma, liver fibrosis, mixed infection, nonhuman, practice guideline, Review, viral clearance",

author = "M. Vigan{\`o} and M. Andreoni and C.F. Perno and A. Crax{\`i} and A. Aghemo and A. Alberti and P. Andreone and S. Babudieri and S. Bonora and M.R. Brunetto and R. Bruno and S. Bruno and V. Calvaruso and N. Caporaso and F. Cartabellotta and F. Ceccherini-Silberstein and V. Cento and A. Ciancio and P. Colombatto and N. Coppola and {Di Marco}, V. and {Di Perri}, G. and S. Fagiuoli and G.B. Gaeta and A. Gasbarrini and P. Lampertico and A. Pellicelli and T. Prestileo and M. Puoti and G. Raimondo and G. Rizzardini and G. Taliani and A.L. Zignego",

note = "Export Date: 2 May 2019 CODEN: ERATC Correspondence Address: Vigan{\`o}, M.; Hepatology Unit, Ospedale San Giuseppe, University of Milan, Via S. Vittore 12, Italy; email: mauro.vigano@tin.it",

year = "2019",

doi = "10.1080/14787210.2019.1563755",

language = "English",

volume = "17",

pages = "117--128",

journal = "Expert Review of Anti-Infective Therapy",

issn = "1478-7210",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Real life experiences in HCV management in 2018

AU - Viganò, M.

AU - Andreoni, M.

AU - Perno, C.F.

AU - Craxì, A.

AU - Aghemo, A.

AU - Alberti, A.

AU - Andreone, P.

AU - Babudieri, S.

AU - Bonora, S.

AU - Brunetto, M.R.

AU - Bruno, R.

AU - Bruno, S.

AU - Calvaruso, V.

AU - Caporaso, N.

AU - Cartabellotta, F.

AU - Ceccherini-Silberstein, F.

AU - Cento, V.

AU - Ciancio, A.

AU - Colombatto, P.

AU - Coppola, N.

AU - Di Marco, V.

AU - Di Perri, G.

AU - Fagiuoli, S.

AU - Gaeta, G.B.

AU - Gasbarrini, A.

AU - Lampertico, P.

AU - Pellicelli, A.

AU - Prestileo, T.

AU - Puoti, M.

AU - Raimondo, G.

AU - Rizzardini, G.

AU - Taliani, G.

AU - Zignego, A.L.

N1 - Export Date: 2 May 2019 CODEN: ERATC Correspondence Address: Viganò, M.; Hepatology Unit, Ospedale San Giuseppe, University of Milan, Via S. Vittore 12, Italy; email: mauro.vigano@tin.it

PY - 2019

Y1 - 2019

KW - Antiviral therapy

KW - chronic liver disease

KW - DAAs

KW - HCV

KW - hepatitis C virus

KW - antivirus agent

KW - glecaprevir plus pibrentasvir

KW - nonstructural protein 5A inhibitor

KW - pibrentasvir

KW - sofosbuvir

KW - sofosbuvir plus velpatasvir plus voxilaprevir

KW - velpatasvir

KW - antiviral resistance

KW - antiviral susceptibility

KW - antiviral therapy

KW - decompensated liver cirrhosis

KW - disease burden

KW - drug efficacy

KW - drug response

KW - drug safety

KW - health care access

KW - hepatitis B

KW - Hepatitis B virus

KW - hepatitis C

KW - Hepatitis C virus

KW - human

KW - Human immunodeficiency virus infection

KW - Italy

KW - kidney failure

KW - liver cell carcinoma

KW - liver fibrosis

KW - mixed infection

KW - nonhuman

KW - practice guideline

KW - Review

KW - viral clearance

U2 - 10.1080/14787210.2019.1563755

DO - 10.1080/14787210.2019.1563755

M3 - Article

VL - 17

SP - 117

EP - 128

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 2

ER -